Taro adds new member to board
HAWTHORNE, N.Y. — Taro Pharmaceutical Industries recently appointed a new member to its board, following the resignation of Hasmukh Shah.
Shah, who cited personal reasons for leaving the drug maker’s board, was replaced by Dov Pekelman, who currently serves as chairman of both Atera Networks and Gilon Investments. Pekelman also served as senior consultant for Teva Pharmaceutical Industries from 1985 to 2008.
Pekelman will serve until Taro’s next annual general meeting of shareholders.
Amneal launches generic Felbatol
BRIDGEWATER, N.J. — Amneal last month launched its version of an epilepsy treatment.
The drug maker said that felbamate tablets are available in 400-mg and 600-mg strengths, following approval from the Food and Drug Administration last month. The drug is the first-to-market generic equivalent of Meda Pharmaceuticals’ Felbatol, Amneal said.
The Amneal generic is available in 90-count bottles in 400-mg strength and 90- and 180-count sizes in 600-mg strength, the company said.
Annual U.S. sales of Felbatol totaled $43.7 million, according to IMS Health data.
Report: Supreme Court rejects Mylan appeal
NEW YORK — Mylan may have to pay $77 million to four health insurers over allegations that it sought to control the market on ingredients used for two anti-anxiety medicines, according to published reports.
Bloomberg reported that the Supreme Court rejected the drug maker’s appeal of a 2005 jury verdict in a case that involved antitrust allegations regarding the drugs lorazepam and clorazepate.
The news agency reported that Mylan had argued that federal courts lacked authority to consider the case, and that an appeals court had told a trial judge to cut the award down instead of dismissing the suit. The article noted that the company has faced antitrust allegations concerning the drugs since 2000, with the Federal Trade Commission complaining that exclusive supply agreements allowed Mylan to raise the price of the drugs by more than 2,500%.
Mylan did not respond to a Drug Store News request for comment.